Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/17479
Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement
StatisticsItem usage statistics
MetadataShow Dublin Core item record
AuthorOtero-Romero, S.; Rodriguez-Garcia, Juan; Vilella, Angels; Ara, J. R.; Brieva, L.; Calles-Hernandez, M. Carmen ; Carmona, O.; Casanova, V; Costa-Frossard, L.; Eichau, Sara; Garcia-Merino, J. A.; Garcia-Vidal, C.; Gonzalez-Platas, M.; Llaneza, M.; Martinez-Gines, M.; Meca-Lallana, J. E.; Prieto, J. M.; Rodriguez-Antiguedad, A.; Tintore, M.; Blanco, Y.; Moral, E.; Grp Enfermedades Desmielizantes SE
Document typeresearch article
CitationOtero-Romero S, Rodriguez-Garcia J, Vilella A, Ara J R, Brieva L, Calles C, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. 2021 Jan;36(1):50-60. Epub 2020 Jun 17.
Background: The recent development of highly effective treatments for multiple sclerosis (MS) and the potential risk of infectious complications require the development of prevention and risk minimisation strategies. Vaccination is an essential element of the management of these patients. This consensus statement includes a series of recommendations and practical scenarios for the vaccination of adult patients with MS who are eligible for highly effective immunosuppressive treatments. Methodology: A formal consensus procedure was followed. Having defined the scope of the statement, we conducted a literature search on recommendations for the vaccination of patients with MS and specific vaccination guidelines for immunosuppressed patients receiving biological therapy for other conditions. The modified nominal group technique methodology was used to formulate the recommendations. Development: Vaccination in patients who are candidates for immunosuppressive therapy should be considered before starting immunosuppressive treatment providing the patient's clinical situation allows. Vaccines included in the routine adult vaccination schedule, as welt as some specific ones, are recommended depending on the pre-existing immunity status. If immunosuppressive treatment is already established, live attenuated vaccines are contraindicated. For vaccines with a correlate of protection, it is recommended to monitor the serological response in an optimal interval of 1-2 months from the last dose.